Cargando…

Elevated plasma Galectin-3 is associated with major adverse kidney events and death after ICU admission

BACKGROUND: Galectin-3 (Gal-3) is a proinflammatory and profibrotic protein especially overexpressed after Acute Kidney Injury (AKI). The early renal prognostic value of Gal-3 after AKI in critically ill patients remains unexplored. The objective was to evaluate the prognostic value of plasma level...

Descripción completa

Detalles Bibliográficos
Autores principales: Boutin, L., Legrand, M., Sadoune, M., Mebazaa, A., Gayat, E., Chadjichristos, C. E., Dépret, F.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8740042/
https://www.ncbi.nlm.nih.gov/pubmed/34991653
http://dx.doi.org/10.1186/s13054-021-03878-x
_version_ 1784629229180157952
author Boutin, L.
Legrand, M.
Sadoune, M.
Mebazaa, A.
Gayat, E.
Chadjichristos, C. E.
Dépret, F.
author_facet Boutin, L.
Legrand, M.
Sadoune, M.
Mebazaa, A.
Gayat, E.
Chadjichristos, C. E.
Dépret, F.
author_sort Boutin, L.
collection PubMed
description BACKGROUND: Galectin-3 (Gal-3) is a proinflammatory and profibrotic protein especially overexpressed after Acute Kidney Injury (AKI). The early renal prognostic value of Gal-3 after AKI in critically ill patients remains unexplored. The objective was to evaluate the prognostic value of plasma level of Gal-3 for Major Adverse Kidney Events (MAKE) and mortality 30 days after ICU admission across AKI stages. METHODS: This is an ancillary study of a prospective, observational, multicenter cohort (FROG-ICU). AKI was defined using KDIGO definition. RESULTS: Two thousand and seventy-six patients had a Gal-3 plasma level measurement at ICU admission. Seven hundred and twenty-three (34.8%) were females and the median age was 63 [51, 74] years. Eight hundred and seven (38.9%) patients developed MAKE, 774 (37.3%) had AKI and mortality rate at 30 days was 22.4% (N = 465). Patients who developed MAKE had higher Gal-3 level at admission compared to patients without (30.2 [20.8, 49.2] ng/ml versus 16.9 [12.7, 24.3] ng/ml, p < 0.001, respectively. The area under the receiver operating characteristic curve of Gal-3 to predict MAKE was 0.76 CI(95%) [0.74–0.78], p < 0.001. Gal-3 was associated with MAKE (OR 1.80 CI(95%) [1.68–1.93], p < 0.001, non-adjusted and OR 1.37 CI(95%) [1.27–1.49], p < 0.001, adjusted). The use of Gal-3 improved prediction performance of prediction model including SAPSII, Screat(adm), pNGAL with a NRI of 0.27 CI(95%)(0.16–0.38), p < 0.001. Median Gal-3 was higher in non-survivors than in survivors at 30 days (29.2 [20.2, 49.2] ng/ml versus 18.8 [13.3, 29.2] ng/ml, p < 0.001, respectively). CONCLUSION: Plasma levels of Gal-3 were strongly associated with renal function, with an increased risk of MAKE and death after ICU admission. Trial registration ClinicalTrials.gov NCT01367093. Registered on 6 June 2011. GRAPHICAL ABSTRACT: [Image: see text] SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s13054-021-03878-x.
format Online
Article
Text
id pubmed-8740042
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-87400422022-01-07 Elevated plasma Galectin-3 is associated with major adverse kidney events and death after ICU admission Boutin, L. Legrand, M. Sadoune, M. Mebazaa, A. Gayat, E. Chadjichristos, C. E. Dépret, F. Crit Care Research BACKGROUND: Galectin-3 (Gal-3) is a proinflammatory and profibrotic protein especially overexpressed after Acute Kidney Injury (AKI). The early renal prognostic value of Gal-3 after AKI in critically ill patients remains unexplored. The objective was to evaluate the prognostic value of plasma level of Gal-3 for Major Adverse Kidney Events (MAKE) and mortality 30 days after ICU admission across AKI stages. METHODS: This is an ancillary study of a prospective, observational, multicenter cohort (FROG-ICU). AKI was defined using KDIGO definition. RESULTS: Two thousand and seventy-six patients had a Gal-3 plasma level measurement at ICU admission. Seven hundred and twenty-three (34.8%) were females and the median age was 63 [51, 74] years. Eight hundred and seven (38.9%) patients developed MAKE, 774 (37.3%) had AKI and mortality rate at 30 days was 22.4% (N = 465). Patients who developed MAKE had higher Gal-3 level at admission compared to patients without (30.2 [20.8, 49.2] ng/ml versus 16.9 [12.7, 24.3] ng/ml, p < 0.001, respectively. The area under the receiver operating characteristic curve of Gal-3 to predict MAKE was 0.76 CI(95%) [0.74–0.78], p < 0.001. Gal-3 was associated with MAKE (OR 1.80 CI(95%) [1.68–1.93], p < 0.001, non-adjusted and OR 1.37 CI(95%) [1.27–1.49], p < 0.001, adjusted). The use of Gal-3 improved prediction performance of prediction model including SAPSII, Screat(adm), pNGAL with a NRI of 0.27 CI(95%)(0.16–0.38), p < 0.001. Median Gal-3 was higher in non-survivors than in survivors at 30 days (29.2 [20.2, 49.2] ng/ml versus 18.8 [13.3, 29.2] ng/ml, p < 0.001, respectively). CONCLUSION: Plasma levels of Gal-3 were strongly associated with renal function, with an increased risk of MAKE and death after ICU admission. Trial registration ClinicalTrials.gov NCT01367093. Registered on 6 June 2011. GRAPHICAL ABSTRACT: [Image: see text] SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s13054-021-03878-x. BioMed Central 2022-01-06 /pmc/articles/PMC8740042/ /pubmed/34991653 http://dx.doi.org/10.1186/s13054-021-03878-x Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Boutin, L.
Legrand, M.
Sadoune, M.
Mebazaa, A.
Gayat, E.
Chadjichristos, C. E.
Dépret, F.
Elevated plasma Galectin-3 is associated with major adverse kidney events and death after ICU admission
title Elevated plasma Galectin-3 is associated with major adverse kidney events and death after ICU admission
title_full Elevated plasma Galectin-3 is associated with major adverse kidney events and death after ICU admission
title_fullStr Elevated plasma Galectin-3 is associated with major adverse kidney events and death after ICU admission
title_full_unstemmed Elevated plasma Galectin-3 is associated with major adverse kidney events and death after ICU admission
title_short Elevated plasma Galectin-3 is associated with major adverse kidney events and death after ICU admission
title_sort elevated plasma galectin-3 is associated with major adverse kidney events and death after icu admission
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8740042/
https://www.ncbi.nlm.nih.gov/pubmed/34991653
http://dx.doi.org/10.1186/s13054-021-03878-x
work_keys_str_mv AT boutinl elevatedplasmagalectin3isassociatedwithmajoradversekidneyeventsanddeathaftericuadmission
AT legrandm elevatedplasmagalectin3isassociatedwithmajoradversekidneyeventsanddeathaftericuadmission
AT sadounem elevatedplasmagalectin3isassociatedwithmajoradversekidneyeventsanddeathaftericuadmission
AT mebazaaa elevatedplasmagalectin3isassociatedwithmajoradversekidneyeventsanddeathaftericuadmission
AT gayate elevatedplasmagalectin3isassociatedwithmajoradversekidneyeventsanddeathaftericuadmission
AT chadjichristosce elevatedplasmagalectin3isassociatedwithmajoradversekidneyeventsanddeathaftericuadmission
AT depretf elevatedplasmagalectin3isassociatedwithmajoradversekidneyeventsanddeathaftericuadmission